Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873352 · ClinicalTrials.gov registry record · Phase 3
Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
A Phase 3 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT01873352: Completed Phase 3 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
NCT01873352 is a Phase 3 study that has completed, run by Meshalkin Research Institute of Pathology of Circulation. The registered enrollment target is 302 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01873352, a Phase 3 study, has completed, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The objective of this trial is to determine the role of renal sympathetic denervation in the prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.
Interventions
- PROCEDURE catheter ablation
- PROCEDURE renal sympathetic denervation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2013-06-20 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 3 |
What the finished NCT01873352 record still lists
NCT01873352 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which catheter ablation is the first listed.
NCT01873352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01873352 about?
NCT01873352 is a clinical study titled "Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation". The objective of this trial is to determine the role of renal sympathetic denervation in the prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual t...
What is the current status of trial NCT01873352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2013-06-20. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT01873352?
The interventions under investigation include: catheter ablation (PROCEDURE), renal sympathetic denervation (PROCEDURE).
Who is sponsoring clinical trial NCT01873352?
This trial is sponsored by Meshalkin Research Institute of Pathology of Circulation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01873352's enrollment target sits among peer trials
302 1119th of 2000 higher than 880 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI